Executive summary: indonesian guidelines on polycystic ovary syndrome management
- Author:
Mila MAIDARTI
1
;
Achmad Kemal HARZIF
;
Amalia SHADRINA
;
Nafi'atul UMMAH
;
Wiryawan PERMADI
;
Author Information
- Publication Type:Original Article
- From:Obstetrics & Gynecology Science 2025;68(3):221-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:Polycystic ovary syndrome (PCOS) is a gynecological, endocrine condition characterized by ovulatory disorders, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. PCOS has significant metabolic and reproductive implications that affect the quality of life of women. This PCOS guideline summary is based on the Indonesian Reproductive Endocrinology and Fertility Association guidelines for PCOS. This guideline is expected to guide the diagnosis and long-term management of PCOS.
Methods:We searched scientific evidence on the Cochrane and PubMed databases using the keyword “polycystic ovary syndrome”. This evidence was reviewed by experts in the field of obstetrics and gynecology, and recommendations were made based on scientific evidence while considering patient values, costs, and resources.
Results:A total of 127 recommendations and practice points were made regarding the diagnosis and management of PCOS. The levels of available health services and management algorithms for PCOS in Indonesia are also included.
Conclusion:The first-line treatment for managing hyperandrogenism and menstrual disorders in patients with PCOS is combined oral contraceptives. The first-line treatment for ovulation induction is letrozole, while clomiphene citrate, metformin, gonadotropins, and ovarian surgery serve as the second-line treatment. The third-line treatments included in vitro fertilization, with or without in vitro maturation.
